This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Labcorp (LH) Completes Strategic Deal With Jefferson Health
by Zacks Equity Research
Labcorp's (LH) agreement with Jefferson to build academic collaborations around teaching and developing innovative tests.
Labcorp (LH) Inks Asset Acquisition Deal With Legacy Health
by Zacks Equity Research
Labcorp's (LH) new agreement with Legacy Health will broaden access to its Diagnostics capabilities and improve services.
Should Value Investors Buy Laboratory Corp. of America (LH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
LabCorp (LH) Partners With Forge Biologics for Gene Therapies
by Zacks Equity Research
LabCorp's (LH) latest partnership will significantly assist patients gain access to cutting-edge, potentially life-saving medication.
Labcorp (LH) Announces Completion of the Fortrea Spin-off
by Zacks Equity Research
Labcorp (LH) completes the planned spin-off of Fortrea to operate as an independent clinical development business.
LabCorp (LH) Gives Update as Fortrea Spinoff Nears Closure
by Zacks Equity Research
Fortrea is set to comprise Labcorp's (LH) Clinical Development and Commercialization Services businesses.
LabCorp (LH) Provides Update on Planned Spinoff of Fortrea
by Zacks Equity Research
After separation from LabCorp (LH), Fortrea is set to operate as a global contract research organization that offers comprehensive drug and medical device development services.
LabCorp (LH) Expands Precision Oncology With Biopsy Test
by Zacks Equity Research
The addition of Labcorp Plasma Focus marks a pivotal step in the expansion of LabCorp's (LH) suite of precision oncology tests.
Why Is LabCorp (LH) Down 2.7% Since Last Earnings Report?
by Zacks Equity Research
LabCorp (LH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
LabCorp (LH) Expands Laboratory Relationship With New Pact
by Zacks Equity Research
LabCorp's (LH) recent partnership will expand healthcare access, offer advanced diagnostic tools and guarantee that both patients and doctors can afford the treatments they get.
Here's Why Investors Should Retain LabCorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) on strategic partnerships and upbeat guidance.
LabCorp (LH) Base Business Growth Strong, Margin Pressure Stays
by Zacks Equity Research
LabCorp (LH) is progressing well with its planned spin-off of the Clinical Development business, which is expected to be completed in mid-2023.
The Zacks Analyst Blog Highlights BioRad Laboratories, Henry Schein, Insulet, Abbott and LabCorp
by Zacks Equity Research
BioRad Laboratories, Henry Schein, Insulet, Abbott and LabCorp are included in this Analyst Blog.
3 MedTech Stocks Likely to Beat Estimates in Q1 Earnings
by Urmimala Biswas
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how BIO, HSIC and PODD are poised ahead of their earnings releases.
LabCorp (LH) Q1 Earnings Miss Estimates, Margins Decline
by Zacks Equity Research
The decline in COVID-19 PCR and antibody testing sales, the severe foreign exchange headwind and inflationary pressure hurt LabCorp's (LH) business performance in Q1.
Compared to Estimates, LabCorp (LH) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for LabCorp (LH) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
LabCorp (LH) Misses Q1 Earnings Estimates
by Zacks Equity Research
LabCorp (LH) delivered earnings and revenue surprises of -4.26% and 0.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
LabCorp (LH) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Ongoing sales rebound in the base business for both Diagnostics and Drug Development segments is likely to have benefited LabCorp (LH) in Q1.
LabCorp (LH) Expands Colon Cancer Test Access With New Pact
by Zacks Equity Research
LabCorp's (LH) at-home collection kit will offer patients an additional and easier option to get screened for colon cancer.
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Here's Why Investors Should Retain LabCorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) backed by strength in its Drug Development business.
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
LabCorp (LH) Focuses on High-Growth Areas Amid Currency Woe
by Zacks Equity Research
In its efforts to expand further, LabCorp (LH) is focusing more on high-growth opportunity areas such as neurodegenerative, autoimmune and liver disease as well as cell and gene therapy.
The Zacks Analyst Blog Highlights TotalEnergies, America Movil, Palo Alto Networks, Manulife Financial and Laboratory Corporation of America
by Zacks Equity Research
TotalEnergies, America Movil, Palo Alto Networks, Manulife Financial and Laboratory Corporation of America are included in this Analyst Blog.
Top Stock Reports for TotalEnergies, America Movil & Palo Alto Networks
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including TotalEnergies SE (TTE), America Movil, S.A.B. de C.V. (AMX) and Palo Alto Networks, Inc. (PANW).